

National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2018Apr19

2018Apr19 HIV Serology Panel					
Panel Sample	True Status	Labs Reporting Incorrect Status			
А	HIV-1 Ag Positive				
В	HIV-2 Ab Positive	Incorrect Status	• HV80		
с	HIV-1/2 Ag/Ab Negative	Incorrect Status	• HV01		
D	HIV-1 Ab Positive	Incorrect Status	HV80HV18		
E	HIV-1/2 Ag/Ab Negative	Incorrect Status	• HV01		

Incorrect interpretations based on their assay result(s):

🏲 <u>HV01</u>

Incorrectly reported a negative sample (Sample C and E) as HIV-1/2 Ag/Ab negative and HIV Ab positive

🖰 <u>НV80</u>

Incorrectly reported the wrong sample status (Sample B and D) based on the assay used in the testing.

🏲 <u>HV18</u>

Incorrectly reported the wrong sample status (Sample D) and did not provide a recommendation



National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada

HIV Serology Quality Assessment Program <u>Final Report for Panel HIVSER 2018apr19</u>

Issued August-15-2018

Introduction

The NLHRS distributed the 2018Apr19 panel on Oct 11th 2017. This final report is specific to the 2018Apr19 panel only and is publicly available; however the identity of participants is not disclosed.

Panel Samples, HIV Test Kits and Data Entry

- Panel Composition
 - 2018Apr19 HIV Serology Panel: Five samples; two HIV negative (C, E), one HIV-2 Ab positive (B), one HIV-1 Ab positive (D), and one HIV-1 Ag positive (A). Samples A, B, and D were diluted with defibrinated human plasma (Basematrix 53, Seracare Life Sciences). Testing and characterization by the NLHRS prior to shipment are presented in Appendix 2. Panels were sent to 43 participants including the NLHRS on Oct 11th, 2017. The deadline for data entry for the 2018Apr19 panel was April 19th, 2018.
- HIV Test Kits Nine different assays were used by the 42 participants excluding the NLHRS who
 returned results (Table 1, Figure 1, and Figure 2). The majority of participants, 83% (36/42) used a
 4th generation HIV immunoassay. The Bio-Rad Geenius HIV-1/2 Confirmatory Assay is now being
 used by participants that do HIV confirmatory testing.
- Data entry The NLHRS Quality Assessment Program used the web based Survey Monkey system to capture results.

_		# of Users			
Туре	Assay	2017Arp19	2017Oct27	2018Apr19	
	Abbott ARCHITECT HIV Ag/Ab Combo CMIA	30	32	32	
	AthAbbott ARCHITECT HIV Ag/Ab Combo CMIA3032AthRoche Elecsys HIV Combi ECLIA22Siemens ADVIA Centaur HIV Ag/Ab Combo (CHIV) ChLIA Assay22Bio-Rad Genscreen ULTRA HIV Ag/Ab013rd onBio-Rad GS HIV-1/HIV-2 PLUS O EIA213rd onBio-Rad Genetic System HIV-2 EIA10Bio-Rad Genetic System HIV-2 EIA101Alere Determine HIV-1/2000bioMerieux VIDAS HIV p24 II ELFA22	2			
Screen – 4 th Generation		2	2	2	
	Bio-Rad Genscreen ULTRA HIV Ag/Ab	0	1	1	
Screen – 3 rd Generation	Bio-Rad GS HIV-1/HIV-2 PLUS O EIA	2	1	0	
Screen – 3 rd Generation – HIV2	Bio-Rad Genetic System HIV-2 EIA	1	0	0	
Caroon Danid tast	bioLytical INSTI HIV-1/HIV-2 Antibody Test Kit	4	2017Oct27 32 2 2 1 1 0 4 0	4	
Screen – Rapid test	Alere Determine HIV-1/2	0	0	1	
6	bioMerieux VIDAS HIV p24 II ELFA	2	2	2	
Confirmatory – p24	Bio-Rad Genscreen HIV-1 Ag EIA	1	1	1	
Confirmentom	Bio-Rad Geenius HIV-1/2 Confirmatory Assay	6	11	11	
Confirmatory – Ab	Bio-Rad Genetic System HIV-1 Western Blot	3	0	0	




Figure 1: Breakdown of the screening assays used by the 42 participants in the 2018Apr19 HIV serology panel (excludes the NLHRS).




Figure 2: Breakdown of the confirmatory assays used by the participants in the 2018Apr19 HIV serology panel (excludes the NLHRS).

Table 2: Level of the different flags and causes for the flag.				
Level of flag Causes for flagging				
Major Incorrect result/status provided				
Intermediate	Deviation from kit insert, unresolved status without recommendation			
Minor	Minor errors that do not result in misinterpretation of the true status of the sample, unresolved status but made a recommendation			

Homogeneity and stability

- Panel members of the 2018Apr19 HIV serology panel were randomly selected for testing by the NLHRS during the 2018Apr19 test event. The homogeneity and stability of the panel samples were assessed by comparing the results submitted by the participants for the 2018Apr19 and 2017Oct27 panels.
- There is no indication of heterogeneity or instability of the panel samples as the results are concordant with the participants and are consistent with the expected results from the NLHRS characterization of each panel member (Tables 3, 4, and Appendix 2).

External QC and QA activities

- 1. *External quality control (QC) material* Used in addition to controls provided in kits; allows users to detect technical problems and assay sensitivity from lot to lot.
 - 21 participants (50%, 21/42) reported using external QC material. Figure 3 illustrates the source of the external control used.




Figure 3: Source of external quality control used in the 2018Apr19 HIV serology panel.

- 2. Quality Assurance (QA) programs Allows participants to evaluate their overall use of the assay and reporting of the results
 - o 39 of 42 participants reported participation in other quality assurance programs (Figure 4).





Figure 4: Distribution of external quality assurance programs which participants are enrolled in other than the NLHRS QAP.

Participants' feedback

- Overall, 41 of 42 participants provided feedback regarding the 2018Apr19 HIV serology survey. Thirty-seven participants preferred the changes made to the survey but 4 participants did not (Figure 5).
- Several areas of improvement for the next survey were identified by the participants (Figure 6).






Figure 5: Participants' responses when asked if they liked the changes made to the 2018Apr19 survey

What changes you would like to see for the next survey?

Figure 6: Participants' responses when asked which area requires improvement in the NLHRS HIV serology survey.

end: Major	Intermediate	Minor				
Table 3: 2018Apr19 HIV Serology Panel final status reported from participants using screening assay only.						
SAMPLE A <u>HIV-1 Ag Positive</u>	SAMPLE B <u>HIV-2 Ab Positive</u>	SAMPLE C <u>Negative</u>	SAMPLE D <u>HIV-1 Ab Positive</u>	SAMPLE E <u>Negative</u>		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ab Negative ¹	HIV-1/2 Ab Positive ¹	HIV-1/2 Ab Negative ¹	HIV-1/2 Ab Positive ¹	HIV-1/2 Ab Negative ¹		
HIV-1/2 Ab Negative ¹	HIV-1/2 Ab Positive ¹	HIV-1/2 Ab Negative ¹	HIV-1/2 Ab Positive ¹	HIV-1/2 Ab Negative ¹		
HIV-1/2 Ab Negative ¹	HIV-1/2 Ab Positive ¹	HIV-1/2 Ab Negative ¹	HIV-1/2 Ab Positive ¹	HIV-1/2 Ab Negative ¹		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
Would not report based on result ¹	Would not report based on result ¹	HIV-1/2 Ag/Ab Negative ¹	Would not report based on result ¹	HIV-1/2 Ag/Ab Negative ¹		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
Would not report based on result ¹	Would not report based on result ¹	HIV-1/2 Ag/Ab Negative	Would not report based on result ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative ¹		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative	HIV-1/2 Ag/Ab Positive ¹	HIV-1/2 Ag/Ab Negative		
HIV-1/2 Ab Negative ¹	HIV-1/2 Ab Positive ¹	HIV-1/2 Ab Negative ¹	HIV-1/2 Ab Positive ¹	HIV-1/2 Ab Negative ¹		
	3: 2018Apr19 HIV Set SAMPLE A HIV-1 Ag Positive HIV-1/2 Ag/Ab Positive ¹ HIV-1/2 Ag/Ab Positive ^{1,2} HIV-1/2 Ag/Ab Positive ¹ <td>3: 2018Apr19 HIV Serology Panel final stateSAMPLE A HIV-1A g PositiveHIV-1A g PositiveSAMPLE B HIV-2 Ab Positive1HIV-1/2 Ag/Ab Positive1HIV-1/2 Ag/Ab Positive1HIV-1/2 Ag/Ab Positive1HIV-1/2 Ag/Ab Positive1HIV-1/2 Ag/Ab Positive1.2HIV-1/2 Ab Negative1.1HIV-1/2 Ab Positive1.2HIV-1/2 Ag/Ab Positive1.2HIV-1/2 Ag/Ab Positive1.2HIV-1/2 Ag/Ab Positive1.1HIV-1/2 Ag/Ab Positive1.2HIV-1/2 Ag/Ab Positive1.1HIV-1/2 Ag/Ab Positive1.2<</td> <td>3: 2018Apr19 HIV Serology Panel final status reported from prostation of the status of the status reported from prostation of the status of th</td> <td>32:2018Apr19 HIV Serology Panel final status reported from participants using screets SAMPLE A SAMPLE B SAMPLE C SAMPLE C HIV-12 Ag/Ab Positive¹ HIV-2 Ag/Ab Positive¹ HIV-1/2 Ag/Ab Positive¹ HIV-1/2 Ag/Ab Positive¹ HIV-12 Ag/Ab Positive¹ HIV-12 Ag/Ab Positive¹ HIV-1/2 Ag/Ab Positive¹ HIV-1/2 Ag/Ab Positive¹ HIV-12 Ag/Ab Positive¹ HIV-12 Ag/Ab Positive¹ HIV-1/2 Ag/Ab Positive¹ HIV-1/2 Ag/Ab Positive¹ HIV-1/2 Ag/Ab Positive¹² HIV-1/2 Ag/Ab Positive¹² HIV-1/2 Ag/Ab Positive¹² HIV-1/2 Ag/Ab Positive¹² HIV-1/2 Ag/Ab Positive¹² HIV-1/2 Ag/Ab Positive¹² HIV-1/2 Ag/Ab Positive¹² HIV-1/2 Ag/Ab Positive¹² HIV-1/2 Ag/Ab Positive¹² HIV-1/2 Ag/Ab Positive¹² HIV-1/2 Ag/Ab Positive¹³ HIV-1/2 Ag/Ab Positive¹⁴ HIV-1/2 Ag/Ab Positive¹³ HIV-1/2 Ag/Ab Positive¹⁴ HIV-1/2 Ag/Ab Positive¹⁴ HIV-1/2 Ag/Ab Positive¹⁴ HIV-1/2 Ag/Ab Positive¹⁴ HIV-1/2 Ag/Ab Positive¹⁴ HIV-1/2 Ag/Ab Positive¹ HIV-1/2 Ag/Ab Positive¹ HIV-1/2 Ag/Ab Positive¹⁴ HIV-1/2 Ag/Ab Positive¹ HIV-1/2 Ag/Ab Positive¹ HIV-1/2 Ag/Ab Positive¹ HIV-1/2 Ag/Ab Positive¹ HIV-1/2 Ag/Ab Positive¹ HIV-1/2 Ag/Ab Positive¹<!--</td--></td>	3: 2018Apr19 HIV Serology Panel final stateSAMPLE A HIV-1A g PositiveHIV-1A g PositiveSAMPLE B HIV-2 Ab Positive1HIV-1/2 Ag/Ab Positive1HIV-1/2 Ag/Ab Positive1HIV-1/2 Ag/Ab Positive1HIV-1/2 Ag/Ab Positive1HIV-1/2 Ag/Ab Positive1.2HIV-1/2 Ab Negative1.1HIV-1/2 Ab Positive1.2HIV-1/2 Ag/Ab Positive1.2HIV-1/2 Ag/Ab Positive1.2HIV-1/2 Ag/Ab Positive1.1HIV-1/2 Ag/Ab Positive1.2HIV-1/2 Ag/Ab Positive1.1HIV-1/2 Ag/Ab Positive1.2<	3: 2018Apr19 HIV Serology Panel final status reported from prostation of the status of the status reported from prostation of the status of th	32:2018Apr19 HIV Serology Panel final status reported from participants using screets SAMPLE A SAMPLE B SAMPLE C SAMPLE C HIV-12 Ag/Ab Positive ¹ HIV-2 Ag/Ab Positive ¹ HIV-1/2 Ag/Ab Positive ¹ HIV-1/2 Ag/Ab Positive ¹ HIV-12 Ag/Ab Positive ¹ HIV-12 Ag/Ab Positive ¹ HIV-1/2 Ag/Ab Positive ¹ HIV-1/2 Ag/Ab Positive ¹ HIV-12 Ag/Ab Positive ¹ HIV-12 Ag/Ab Positive ¹ HIV-1/2 Ag/Ab Positive ¹ HIV-1/2 Ag/Ab Positive ¹ HIV-1/2 Ag/Ab Positive ¹² HIV-1/2 Ag/Ab Positive ¹³ HIV-1/2 Ag/Ab Positive ¹⁴ HIV-1/2 Ag/Ab Positive ¹³ HIV-1/2 Ag/Ab Positive ¹⁴ HIV-1/2 Ag/Ab Positive ¹ HIV-1/2 Ag/Ab Positive ¹ HIV-1/2 Ag/Ab Positive ¹⁴ HIV-1/2 Ag/Ab Positive ¹ </td		

¹ Further action recommended by participant; "Refer to reference/provincial laboratory for further testing" or "Request a follow-up sample". ² Would not report based on result.

Leger	Legend: Major Intermediate Minor						
Table 4	Table 4: 2018Apr19 HIV Serology Panel final status reported from participants (includes the NLHRS) using						
screening and confirmatory assays.							
LAB	SAMPLE A <u>HIV-1 Ag Positive</u>	SAMPLE B <u>HIV-2 Ab Positive</u>	SAMPLE C <u>Negative</u>	SAMPLE D <u>HIV-1 Ab Positive</u>	SAMPLE E <u>Negative</u>		
HV01	HIV-1/2 Ag/Ab Positive HIV-1/2 Ab Negative ^{1,2}	HIV-1/2 Ag/Ab Positive	HIV-1/2 Ag/Ab Negative HIV-2 Ab Positive	HIV-1/2 Ag/Ab Positive	HIV-1/2 Ag/Ab Negative HIV-1 Ab Positive		
HV02	HIV-1/2 Ab Negative ^{1,2}	HIV-2 Ab Positive ²	HIV-1/2 Ag/Ab Negative	HIV-1 Ab Positive ²	HIV-1/2 Ag/Ab Negative		
HV03	HIV-1/2 Ag/Ab Positive ^{1,2}	HIV-2 Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative	HIV-1 Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative		
HV13	HIV-1/2 Ab Negative ¹ HIV-1 p24 Ag Positive	HIV-2 Ab Positive ^{1,2}	HIV-1/2 Ab Negative HIV-1 p24 Ag Negative	HIV-1 Ab Positive ^{1,2}	HIV-1/2 Ab Negative HIV-1 p24 Ag Negative		
HV15*	HIV-1/2 Ag/Ab Negative*	HIV-2 Ab Positive	HIV-1/2 Ag/Ab Negative	HIV-1 Ab Positive	HIV-1/2 Ag/Ab Negative		
HV16	HIV-1 p24 Ag Positive	HIV-2 Ab Positive	HIV-1/2 Ag/Ab Negative	HIV-1 Ab Positive	HIV-1/2 Ag/Ab Negative		
HV18	HIV-1/2 Ag/Ab Indeterminate ^{1,2}	HIV-2 Ab Positive HIV-1 Ab Indeterminate ^{1,2}	HIV-1/2 Ag/Ab Negative ²	HIV-1/2 Ag/Ab Positive	HIV-1/2 Ag/Ab Negative ²		
HV19	HIV-1/2 Ab Negative HIV-1 p24 Ag positive ¹	HIV-2 Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative ²	HIV-1 Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative ²		
HV20	HIV-1/2 Ab Negative ^{1,2}	HIV-2 Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative ²	HIV-1 Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative ²		
HV21	HIV-1/2 Ab Negative ^{1,2}	HIV-2 Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative ²	HIV-1 Ab Positive ^{1,2}	HIV-1/2 Ag/Ab Negative ²		
HV22	Would not report based on result ¹	HIV-2 Ab Positive	HIV-1/2 Ab Negative	HIV-1 Ab Positive	HIV-1/2 Ab Negative		
HV75	HIV-1/2 Ab Negative	HIV-2 Ab Positive	HIV-1/2 Ab Negative	HIV-1 Ab Positive	HIV-1/2 Ab Negative		
11075	HIV-1 p24 Ag Positive	HIV-1 p24 Ag Negative	HIV-1 p24 Ag Negative	HIV-1 p24 Ag Negative	HIV-1 p24 Ag Negative		
HV80 ³	HIV-1/2 Ab Negative, HIV-1 p24 Ag Positive	HIV-1 Ab Positive,	HIV-1/2 Ab Negative,	HIV-1 Ab Positive,	HIV-1/2 Ab Negative,		
1	TITV-1 PZ4 Ag POSILIVE	HIV-1 p24 Ag Positive	HIV-1 p24 Ag Negative	HIV-1 p24 Ag Positive	HIV-1 p24 Ag Negative		

¹ Further action recommended by participants; "Refer to provincial/reference laboratory for further testing" or "Request a follow-up sample".

² Did not perform standalone HIV-1 p24 testing to confirm the presence of HIV-1 p24 antigen.

³Participant performed both an HIV-1/2 Ab rapid test and a 4th gen HIV immunoassay.

* This participant used a modified confirmatory algorithm which does not account for p24 detection.

Table 5: 2018Apr19 HIV panel sample final HIV serology status based on assay performed.							
Assay	Sample A	Sample B	Sample C	Sample D	Sample E		
Rapid Test	HIV-1/2 Ab						
	Negative	Positive	Negative	Positive	Negative		
4 th Gen HIV	HIV-1/2 Ag/Ab						
Screening Assay	Positive	Positive	Negative	Positive	Negative		
HIV Ab	HIV Ab	HIV-2 Ab	HIV Ab	HIV-1 Ab	HIV Ab		
confirmatory Assay	Negative	Positive	Negative	Positive	Negative		
HIV-1 p24 Ag test	HIV-1 p24 Ag						
	Positive	Negative	Negative	Negative	Negative		

Results

- *Return rate* Results were returned from 97.7% of participants excluding the NLHRS (42/43).
 - **HV74:** Suspended their participation in the NLHRS QAP for HIV serology until their new HIV testing algorithm is implemented.
- Group Analysis (Excluding the NLHRS) 2018Apr19 Panel (Tables 3 and 4)
 - Sample A (HIV-1 Ag Positive) 41/41 participants provided either a correct serology status and/or recommendation.
 - **HV15:** Excluded from the assessment of this sample because the participant only use an HIV Ab confirmatory test for assessment in the NLHRS HIV serology panel.
 - Sample B (HIV-2 Ab Positive) 40/42 participants provided either a correct serology status and/or recommendation.
 - **HV01**: Submitted an incorrect serology status without a follow-up or recommendation, even though it was correctly identified as HIV-2 Ab positive in their testing.
 - **HV80:** Did not perform HIV Ab confirmatory testing but submitted as HIV-1 Ab positive.
 - Sample C (HIV-1/2 Ag/Ab Negative) 40/42 participants provided either a correct serology status and/or recommendation.
 - **HV01:** Submitted an incorrect serology status. It was submitted both as HIV-1/2 Ag/Ab negative and HIV-2 Ab positive.
 - **HV15:** Submitted the serology status as HIV-1/2 Ag/Ab negative despite using an assay that does not detect HIV-1 p24 Ag.
 - Sample D (HIV-1 Ab Positive) 39/42 participants provided either a correct serology status and/or recommendation.
 - **HV01**: Submitted an incorrect serology status without a follow-up or recommendation, even though they correctly identified the sample as HIV-1 Ab positive in their testing.
 - **HV18**: Submitted an incorrect serology status without a follow-up or recommendation, even though they correctly identified the sample as HIV-1 Ab positive in their testing.
 - **HV80**: Did not perform HIV Ab confirmatory testing but submitted as HIV-1 Ab positive.
 - Sample E (HIV-1/2 Ag/Ab Negative) 40/42 participants provided either a correct serology status and/or recommendation.
 - **HV01:** Submitted an incorrect serology status. It was submitted both as HIV-1/2 Ag/Ab negative and HIV-1 Ab positive.
 - **HV15:** Participant used an HIV Ab confirmatory assay but reported the sample as HIV-1/2 Ag/Ab negative.

Results (continued)

• Incorrect final HIV serology status: HV15, HV80

HV80 tested the 2018Apr19 HIV serology panel samples with a 4th Gen screening assay and a rapid test. They did not perform an HIV Ab confirmatory test to confirm sample B as HIV-2 Ab positive and sample D as HIV-1 Ab positive. HV15 reported samples C and E as HIV-1/2 Ag/Ab negative but the assay used only detects HIV-1/2 antibody and not HIV-1 p24 Ag.

• <u>Transcriptional Error :</u> HV01, HV18

HV01 was able to correctly identify the serology status for samples B, D, C, and E but made a transcriptional error when submitting the final result. HV18 made the same transcriptional error for sample D.

Conclusion

Several participants (HV01, HV15, and HV18) made transcriptional errors during the final results submission stage where an incorrect HIV serology status was submitted, or they did not provide a recommendation for a sample with an unresolved HIV status. In all cases, the participants submitted an incorrect result despite correctly identifying the HIV serology status for each sample based on the assay used. To address participant feedback regarding the need for a better reporting format, the NLHRS Quality Assurance Program is currently in the process of developing a new data submission platform that is both more robust and user friendly. This will minimize transcriptional errors that are possibly the result of limitations with our current system for data submission. We anticipate that the new platform will be ready in the near future.

The other error identified in this panel resulted from participant HV80 not realizing the limitation of the assays used in their HIV testing algorithm. In this case, reactive results on both the Alere Determine HIV-1/2 and the Bio-Rad Ultra Combo were used to assign a serology status of HIV-1 Ab positive. Since both tests cannot be used to distinguish between a status of HIV-1 or 2 Ab positive. The correct serology status to report is HIV-1/2 Ab positive.

Participant HV15 was not able to correctly detect the HIV-1 p24 Ag positive sample for 2 consecutive panels, since the Bio-Rad Geenius HIV-1/2 Confirmatory Assay was the only test used for both test events. However, this participant has disclosed that they utilize another assay in their algorithm that would have been able to detect the HIV-1 p24 Ag in sample A. Owing to operational constraints; they were only able to use the Bio-Rad Geenius HIV-1/2 Confirmatory Assay for the NLHRS HIV serology panel. Consequently, the NLHRS will no longer flag participant HV15 in this panel and onward, for reporting a negative result for a sample that is positive for HIV-1 p24 Ag only, as it would not be a fair assessment of their overall testing procedure.

Conclusion (continued)

Proficiency testing programs are designed to test not only the examination stage, but also the overall process in patient sample testing. As outlined in Appendix 3, errors in laboratory and medical testing can also occur during the pre-examination stage, which includes all elements related to specimen collection.

The overall quality of HIV serology testing in Canada remains very high.

We value each laboratory's participation in these QA panels and your suggestions for improvement. The NLHRS is committed to improving all aspects of the HIV serology proficiency testing program in order to provide quality proficiency testing to our participants.

If you would like to make an appeal, please submit your concerns to:

phac.nlhrs-lnsrv.aspc@canada.ca


Thank you for your participation in the NLHRS HIV Serology QA Program

John Ho

Quality Assurance Program Coordinator National Lab for HIV Reference Services Public Health Agency of Canada Tel: (204) 789-6522

Ell

Laboratory Chief National Lab for HIV Reference Services Public Health Agency of Canada Tel: (204) 789-6527



Appendix 1: Adaptation of the Clinical and Laboratory Standards Institute (CLSI) M53-Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection: Approved Guideline Algorithm I.

Appendix 2: Characterization

Sample		C/E (Duplicate)	А	В	D
		Negative	HIV-1 Ag Positive	HIV-2 Ab Positive	HIV-1 Ab Positive
Final Status		HIV-1/2 Ag/Ab Negative	HIV-1 Ag Positive	HIV-2 Ab Positive	HIV-1 Ab Positive
bioLytical INSTI HIV-1/2 Rapid Test	Result	NR	NR	R	R
Bio-Rad GS HIV Ag/Ab Combo	Result	Non Reactive	Reactive	Reactive	Reactive
Bio-Rad GS HIV p24	Result	Non Reactive	Reactive	Non Reactive	Non Reactive
Bio-Rad GS HIV p24 Confirmatory	Result	Not Tested	100% Neutralization	Not Tested	Not Tested
	Result	Neg	Neg	HIV IND	HIV-1
	gp160	-	-	-	++
	gp120	-	-	-	+
	p65	-	-	++	+/-
Bio-Rad GS HIV-1	p55	-	-	-	+
Western Blot	p51	-	-	+	+/-
Western Diot	gp41	-	-	-	++
	p40	-	-	+/-	++
	p31	-	-	++	++
	p24	-	-	+/-	++
	p18	-	-	-	+
	Result	Neg	Neg	HIV-2	HIV-1
	sgp120	-	-	-	++
	gp41	-	-	-	+++
Fujirebio INNO-	p31	-	-	+++	++
LIA HIV-I/II Score	p24	-	-	++	++
	p17	-	-	-	-
	sgp105	-	-	++	-
	gp36	-	-	+++	-
	Result	Neg	Neg	HIV-2	HIV-1
	gp36	-	-	+	-
Bio-Rad Geenius	gp140	-	-	+	-
HIV-1/HIV-2	p31	-	-	+	-
Supplemental	gp160	-	-	-	+
Assay	p24	-	-	-	+
	gp41	-	-	-	+
	CTRL	+	+	+	+

Appendix 3: Troubleshooting

Troubleshooting; common causes of outlying and/or aberrant results in Serology and Molecular Laboratories.

Type of Error	Possible Cause(s)	Pre- Analytical	Analytical	Post- Analytical			
Sample mix-up	Can occur during specimen reception or testing. May result in outlying/aberrant results for one or all samples mixed-up.	~	\checkmark				
	 Incorrect test ordering by physician 	✓					
	 Incorrect shipment address 	\checkmark					
	 Selecting the wrong assay for data entry 	✓					
	 Interchanging results for two or more specimens 			\checkmark			
	Entering incorrect results			\checkmark			
	 Entering values in the incorrect field (e.g., OD as S/Co) 			\checkmark			
Transcription	 Entering values in the incorrect unit (e.g., IU/mL instead of log₁₀ copies/mL) 			✓			
	 Using a comma instead of a dot to denote a decimal point 			\checkmark			
	 Selecting the incorrect assay interpretation or analyte 			\checkmark			
	 Failure to recommend follow-up testing where necessary 			\checkmark			
	It is recommended all results that are manually transcribed or entered electronically be checked by a second individual to avoid transcription errors.						
	Sporadic test results identified as outlying and/or aberrant can be classified as random events. Possible causes of random error include:						
	Incorrect sample storage/shipping conditions	✓	√				
Outlying and/or Aberrant Results (<u>random error</u>)	Incorrect test method	✓	√				
	Insufficient mixing of sample, especially following freezing		√				
	Poor pipetting		\checkmark				
	Ineffective or inconsistent washing		√				
	Transcription errors	✓		✓			
	Cross-contamination or carryover	✓	\checkmark				
	Presence of inhibitors to PCR		\checkmark				
	A series of test results identified as outlying and/or aberrant may be due to a systematic problem. Systematic problems may be due to:						
	Reagents contaminated, expired or subject to batch variation		✓				
	Instrument error or malfunction		✓				
	Insufficient washing		✓				
Outlying and/or	Incorrect wavelength used to read the assay result		✓				
Aberrant	Cycling times too long/short or temperature too high/low		✓				
Results	Incubation time too long/short or temperature too high/low		✓				
(systematic	Insufficient mixing/centrifuging before testing		✓				
<u>error</u>)	Incorrect storage of test kits and/or reagents	✓					
	Contamination of master-mix, extraction areas or equipment		✓				
	Ineffective extraction process		✓				
	Degradation of master-mix components		✓				
	Suboptimal primer design (in-house assays)		✓				
				I			

This table was modified from a report produced by the National Reference Laboratory (NRL), Melbourne, Australia.